HomeBOSTON SCIENTIFIC

BOSTON SCIENTIFIC

Tactra™ Malleable Penile Prosthesis Launched by Boston Scientific

The new penile prosthesis is the first new innovation in penile implants in more than 10 years and represents an evolution in the design of malleable penile implants to offer the patient and his partner a more authentic, natural-feeling erection.

April 24, 2019: LOTUS Edge ™ Aortic Valve System FDA Approval

The LOTUS Edge valve system is the only FDA-approved aortic valve that gives physicians the option to reposition and completely recapture the valve once it has been fully deployed. It also features a braided valve frame and an adaptive seal that minimizes paravalvular regurgitation or leaking (PVL) by conforming to the patient's native aortic valve.

Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device Receives CE Mark

3/13/19: The WATCHMAN device has been implanted in more than 75,000 patients worldwide and we are pleased that this next-generation technology has been granted European regulatory approval so that we can offer it to patients and clinicians throughout Europe.

Boston Scientific Launches Spectra WaveWriter™ Spinal Cord Stimulator System in Europe

1/31/19: Spectra WaveWriter™ Spinal Cord Stimulator allows physicians & patients to specifically target one area of pain, or multiple areas, with one or both types of therapy to address individual needs.

Boston Scientific Exercises Option to Acquire Millipede, Inc.

12/27/18: Acquisition will expand structural heart portfolio to include transcatheter mitral annuloplasty repair system.

Eluvia™ Drug-Eluting Vascular Stent System Receives FDA Approval

9/24/18: The Eluvia stent utilizes a drug-polymer combination to offer sustained release of the drug paclitaxel for a one-year timeframe, designed to prevent tissue regrowth that might otherwise block the stented artery.

LithoVue Empower™ Retrieval Deployment Device is Launched by Boston Scientific

9/21/18: “The LithoVue Empower Device is a unique tool that can improve ureteroscopic stone treatment as it puts the process of stone manipulation entirely into the hands of the surgeon,” said Dr. Brian Matlaga, the Stephens Professor of Urology at Johns Hopkins Medical Institutions and director of stone disease, James Buchanan Brady Urological Institute and presenting author of the data. “Ultimately, the LithoVue Empower Device introduces a novel efficiency into ureteroscopic stone surgery, as it makes it simpler for the urologist to pick up and move a stone – a historic source of frustration for this procedure."

Claret Medical to be Acquired by Boston Scientific

7/20/18: "Through the development and commercialization of the Sentinel System, Claret Medical has successfully introduced a new layer of safety and peace of mind for physicians and their patients undergoing TAVR procedures," said Kevin Ballinger, president, Interventional Cardiology, Boston Scientific.